Because GBM is divided into several subtypes and is highly heterogeneous (3, 57, 58, 59), further in vitro and in vivo studies using additional GBM cell lines and patient tumor tissues are needed to validate the overlapping functions of Crk and CrkL in GBM. The gene discussed is CRKL; the disease is glioblastoma.